Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use

Journal of Drugs in Dermatology

Volumn 12, Issue 10, 2013, Pages 1122-1129

  Brodmerkel, Carrie ^a   Wadman, Eric ^a   Langley, Richard G ^b   Papp, Kim A ^c   Bourcier, Marc ^d   Poulin, Yves ^e   Ho, Vincent ^f   Guenther, Lyn ^g   Kunynetz, Rod ^h   Nigen, Simon ⁱ   Vender, Ronald ^j   Wasel, Norman ^k   Hsu, Ming Chun ^a   Szapary, Philippe ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b DALHOUSIE UNIVERSITY   (Canada)

^c PROBITY MEDICAL RESEARCH   (Canada)

^d Dermatology Clinic   (Canada)

^e Centre Dermatologique du Quebec Metropolitain   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g Guenther Dermatology Research Centre   (Canada)

^h Ultranova Skincare   (Canada)

ⁱ INNOVADERM RESEARCH   (Canada)

^j Dermatrials Research   (Canada)

^k Stratica Medical Canada   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; PNEUMOCOCCUS VACCINE; USTEKINUMAB;

ADULT; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INJECTION SITE REACTION; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PSORIASIS; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; UNSPECIFIED SIDE EFFECT; VACCINATION;

ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PSORIASIS; STREPTOCOCCUS PNEUMONIAE; TETANUS TOXOID; VACCINATION;

EID: 84885462341     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Krueger GG, Langley RG, Leonardi C, et al; for the CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-592.
2. Leonardi CL, Kimball AB, Papp KA, et al; for the PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-1674.
3. Papp KA, Langley RG, Lebwohl M, et al; for the PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-1684.
4. Griffiths CE, Strober BE, van de Kerkhof P, et al; for the ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-128.
5. Reich KK, Papp KA, Griffiths CE, et al; on behalf of the PHOENIX 1, PHOENIX 2, and ACCEPT investigators. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 2012;11:300-312.
6. Kimball AB, Papp KA, Wasfi Y, et al; on behalf of the PHOENIX 1 investigators. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2012 Dec 20. doi: 10.1111/jdv.12046. [Epub ahead of print]
7. Papp KA, Griffiths CE, Gordon K, et al; on behalf of the PHOENIX 1, PHOENIX 2, ACCEPT Investigators. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013;168: 844-854.
8. Looney R J, Diamond B, Holers VM, et al; for the Autoimmunity Centers of Excellence Immunocompetency Committee. Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clin Immunol 2007; 123:235-243.
9. Lynde C, Krell J, Korman N, Mathes B; for the Vaccine Study Investigators. Immune response to pneumococcal polysaccharide vaccine in adults with chronic plaque psoriasis treated with alefacept. J Am Acad Dermatol 2011;65:799-806.
10. Rahier JF, Moutschen M,Van Gompel A, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 2010;49:1815-1827.
11. Gelinck LB, van der Bijl AE, Visser LG, et al. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine. Vaccine 2008;26:3528-3533.
12. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007;34:272-279.
13. Visvanathan S, Keenan GF, Baker DG, et al. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007;34:952-957.
14. Mease PJ, Ritchlin CT, Martin RW, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004;31:1356-1361.
15. Bingham CO, 3rd, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010;62:64-74.
16. Kapetanovic MC, Roseman C, Jönsson G, et al. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum 2011;63:3723-3732.
17. Krueger JG, Ochs HD, Patel P, et al. Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. J Invest Dermatol 2010; 128:2615-2624.
18. Gottlieb AB, Casale TB, Frankel E, et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol 2003;49:816-825.
19. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-1252.
20. Brodmerkel C, Zhu Y, Jiao Q, et al. Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions. J Drugs Dermatol 2010;9:677-683.
21. Pickering JW, Martins TB, Greer RW, et al. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. Am J Clin Pathol 2002;117:589-596.
22. Go ES and Ballas ZK. Anti-pneumococcal antibody response in normal subjects: a meta-analysis. J Allergy Clin Immunol 1996;98:205-215.
23. Hare ND, Smith BJ, Ballas ZK. Antibody response to pneumococcal vaccination as a function of preimmunization titer. J Allergy Clin Immunol 2009;123:195-200.
24. Van der Wielen M, Van Damme P, Joossens E, et al. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine 2000;18:2075-2082.
25. de Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998;280:1435-1438.
26. de Boer T, van Dissel JT, Kuijpers TW, et al. Influenza virus vaccination induces interleukin-12/23 receptor beta 1 (IL-12/23R beta 1)-independent production of gamma interferon (IFN-gamma) and humoral immunity in patients with genetic deficiencies in IL-12/23R beta 1 or IFN-gamma receptor I. Clin Vaccine Immunol 2008;15:1171-1175.